Andrew J. Finan

About Andrew J. Finan

Executive-level attorney and strategic business advisor in the pharmaceutical, medical device, and biotechnology industries. Business-oriented and solutions-focused with broad experience advising and working with executive leadership to identify and mitigate risk and to execute on corporate goals and objectives. Demonstrated ability to manage multiple, complex, evolving, and critical priorities and initiatives to successful completion. Experience with public company SEC compliance and reporting, public and private financing, and supporting pharmaceutical, medical device, and biotech businesses in all stages of product development (from investigational through launch and commercialization).

Experience

1. Vice President, Deputy General Counsel & Head of Compliance

   DBV Technologies

   Mar 2022 — Present

   Strategic advisor and legal counsel for publicly traded, dual-listed (Euronext: DBV; Nasdaq: DBVT) clinical-stage biopharmaceutical company advising on broad range of legal, corporate and compliance issues impacting the Company’s business.• Serve as legal and strategic advisor to Executive team and senior leadership on a broad set of healthcare, commercial, and general corporate matters related to the Company’s ongoing business activities.• Develop, implement and manage global Compliance Program.• Provide ongoing legal advice and strategic guidance to CEO and CFO on, and lead execution of, public and private financing transactions (e.g, follow-on offerings, PIPE, at-the-market, etc.) and strategic transactions, including successful Private Investment in Public Equity (“PIPE”) financing (Mar. 2025) that raised up to $306.9 million, PIPE financing (Jun. 2022) that raised $194 million, and implementation of multiple at-the-market (“ATM”) equity financing programs that raised $30 Million (Oct. 2025),$29.99 Million (Oct. 2025),$15 Million (May 2022) and $7.8 million (Jun. 2023).• Advise Executive team and senior leadership on implications of applicable FDA regulations (e.g, off-label promotion, pre-approval promotion) and fraud and abuse laws (e.g, AKS, FCA) on Company’s product development activities and preparations for commercialization, and collaborate to develop strategies to comply with and mitigate risk associated with the same.• Manage preparation of and compliance with ongoing SEC reporting obligations including, without limitation, Form 10-K Annual Reports, Form 10-Q Quarterly Filings, Form 8-K Periodic Filings, Section 16 Officer and Director Filings (i.e, Forms 3, 4, and 5), Form S-3 and Form S-8 Registration Statements, and Schedule 14A Proxy Statements.• Draft and negotiate all vendor, HCP, facilities, and supply chain contracts (e.g, CDAs, MSAs, consulting agreements, clinical trial agreements, manufacturing agreements, supply agreements).

Education

• New York Law School

  Juris Doctor, cum laude

  2009 — 2012

• University of Rhode Island

  B.A., Political Science

  2003 — 2007

Skills

• Legal Writing
• Westlaw
• Legal Research